Nemeth Endre, Szigeti Szabolcs, Varga Tamas, Daroczi Laszlo, Barati Zoltan, Merkely Bela, Gal Janos
1 Department of Anaesthesia and Intensive Therapy, Semmelweis University, Budapest, Hungary.
2 Heart and Vascular Centre, Semmelweis University, Budapest, Hungary.
Perfusion. 2018 Oct;33(7):593-596. doi: 10.1177/0267659118777442. Epub 2018 May 19.
The acute surgical treatment of infective endocarditis (IE) carries a high risk of postoperative mortality. Most complications are linked to uncontrolled sepsis and inflammatory processes. Cytokine haemoadsorption is an extracorporeal technique which has benefits reported in haemodynamic stability and inflammatory response.
A 46-year-old male patient underwent emergency cardiac surgery due to progressive IE. Postcardiotomy cardiogenic shock associated with cardiac surgery required the implantation of venoarterial (VA)-ECMO. Three days later, the patient developed secondary septic shock. The novel application of continuous CytoSorb treatment installed in the VA-ECMO circuit is demonstrated in this case during the management of simultaneous shocks. Advanced intensive care led to an improvement in the patient's condition, which facilitated successful weaning from mechanical ventilation. However, the patient died from a new onset fulminant septic shock two months after his initial cardiac surgery.
VA-ECMO is suitable for installation of the CytoSorb cartridge. This modality could be an option for high-volume, continuous cytokine haemoadsorption when VA-ECMO is employed without renal replacement therapy.
This specific application of CytoSorb was safe, feasible and contributed to the optimal management of simultaneous shocks.
感染性心内膜炎(IE)的急性外科治疗术后死亡率很高。大多数并发症与败血症和炎症过程控制不佳有关。细胞因子血液吸附是一种体外技术,在血流动力学稳定性和炎症反应方面已报道有诸多益处。
一名46岁男性患者因进行性IE接受了急诊心脏手术。心脏手术后发生的心源性休克需要植入静脉 - 动脉(VA)体外膜肺氧合(ECMO)。三天后,患者出现继发性感染性休克。本病例展示了在VA - ECMO回路中安装连续CytoSorb治疗在同时处理多种休克时的新应用。高级重症监护使患者病情有所改善,这有助于成功撤机。然而,患者在首次心脏手术后两个月死于新发的暴发性感染性休克。
VA - ECMO适合安装CytoSorb滤器。当在未进行肾脏替代治疗的情况下使用VA - ECMO时,这种方式可能是进行大容量、连续细胞因子血液吸附的一种选择。
CytoSorb的这种特定应用是安全、可行的,并有助于对同时发生的休克进行最佳管理。